Dna. Many RNA therapeutics function by targeting transcripts encoded for within DNA.
Turku, Finland – 4th January 2024: One the most major pharmaceutical milestones of our generation has been the advent of nucleic acid based therapies. As many of us know, our lives have already been heavily influenced by nucleic acid therapies, with COVID-19 vaccinations representing the most widespread adoption of RNA as a human therapeutic to date. RNA is increasingly becoming a compelling foundation to many other therapies. With near complete freedom to customize RNA therapeutics to new targets paired with relatively simple and scalable production, the future of RNA therapeutics looks bright, or does it?
Several challenges still hamper the effective use of many RNA therapies, namely within drug delivery. DelSiTech and Astra Zeneca have diligently been working to address some of these challenges by applying Silica Matrix technology to antisense oligonucleotide therapies. Recently, encouraging results from an in vivo preclinical trial of silica-based delivery of an antisense oligonucleotide have spurred further pursuit of a long-acting controlled release drug delivery approach.
We are proud to reflect on the publication as the first ever public account of biodegradable silica microparticle delivery of an antisense oligonucleotide, which reinforces our commitment to continue to innovate in drug delivery science with our partners.
This most recent publication represents a continuation of a series of publications produced by DelSiTech and Astra Zeneca in collaboration. For more information, the article can be found here.